Apellis Pharmaceuticals Announces That APL-2 Met Its Primary Endpoint in a Phase 2 Study in Patients with Geographic Atrophy, an Advanced Form of Age-...
August 24, 2017
MaxCyte, Inc. - First Day of Dealings on AIM
March 30, 2016
Apellis Pharmaceuticals Announces Pricing of Initial Public Offering
November 8, 2017
MaxCyte Presents High Performance, CHO-Based Transgene Expression for Gram Scale Antibody Production Using Flow Electroporation at Informa's 2013 Cell Line Development and Engineering Conference
February 9, 2013
Gaithersburg, Maryland - MaxCyte, Inc., the pioneer in scalable, high performance cell transfection systems, is taking a leadership scientific role in Informas Cell Line Development and Engineering Conference, one of Europe's leading events for the industry, being held February 11-15 in Vienna, Austria. At the conference, MaxCyte will present break-through data in a scientific podium presentation and detail unprecedented antibody production capabilities in a technical poster.
Dr. James Brady, Director of Technical Applications at MaxCyte, will present data using flow electroporation in a podium presentation entitled "Streamlining Antibody Development Using Large Scale, CHO Transient Gene Expression (TGE)" on Monday, February 11, at 11:30 AM. "Dr. Bradys presentation demonstrates how the MaxCyte STX Scalable Transfection System and the MaxCyte VLX Large Scale Transfection System perform the dual role of scalable, high titer transient expression for early stage screening and characterization, and enable rapid generation of stable cell lines for later stage biotherapeutic development," says Dr. Karen Donato, Executive Vice President of Global Business Development & Marketing at MaxCyte. "By using the MaxCyte flow electroporation platform, biopharmaceutical companies are improving the speed, biological relevance, and process design for their antibody screening and production."
"Informas Cell Line Development and Engineering Conference brings together individuals from leading industry and academic institutes to discuss the latest cutting-edge research and applications in cell line development with the goal of improving cell line quality, maximizing protein production, and increasing the efficiency of biopharmaceutical development pipelines," says Douglas Doerfler, President, and CEO of MaxCyte. "MaxCyte flow electroporation plays a unique role in addressing these challenges, bringing capabilities that can dramatically improve costs, timelines, and quality of outcomes. We look forward to presenting our powerful, enabling platform to this key audience."
MaxCyte will also present a scientific poster entitled "Streamlining Antibody Development Using Large Scale, CHO Transient Gene Expression (TGE) Followed by Rapid Production of CHO Stable Pools" with data demonstrating the utility of the MaxCyte platform at multiple steps in antibody development. MaxCyte scientists will be available throughout the conference for further technical discussions.